Mendoza 2002.

Methods	Randomised controlled trial
Participants	165 women with intact uterus younger than 60 years (mean 50 years), who had been amenorrhoeic for 1 to 5 years (mean 22.3 months). Women who had had a hysterectomy or had received hormone treatment in the 3 months before the trial were excluded, as were those with a history of a malignant gynaecological process, oestrogen‐producing tumour or obesity (body mass index > 32)
Interventions	Tibolone 2.5 mg/d Cyclical combined regimen of transdermal oestrogen and progestogen: transdermal patch of 17β‐oestradiol 50 μg/d during 14 days and transdermal patch of 17β‐oestradiol 50 μg/d plus 0.25 mg/d of norethisterone acetate during the following 14 days Intermittent progesterone regimen: transdermal 17β‐oestradiol 50 μg/d and oral micronised natural progesterone 200 mg twice a week For 1 year
Outcomes	Irregular bleeding, vasomotor symptoms frequency 0 = never, 1 = occasionally, 2 = frequently
Notes	Data on vasomotor symptoms expressed as number of women with reduced symptoms Timing: September 1996 to April 1998 Location: Spain Multi‐centre: no; single site
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was done following a table of random numbers
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Defined as "simple‐blind", but no details given
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Not specified, but given the nature of outcomes assessed, their evaluation is likely to be "objective"
Incomplete outcome data (attrition bias) All outcomes	High risk	32/165 women did not start HRT, no reasons given
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	Unclear risk	Not reported